{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001665","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.192459+00:00","generated_at":"2026-05-28T09:05:03.716733+00:00","sec_items":["1.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AEON Biopharma closes $20M public offering; net proceeds ~$18.3M","bullets":["Gross proceeds ~$20M from 40M common units at $0.50/unit (1 share + 1 Series A + 1 Series B warrant).","Net proceeds after underwriting fees ~$18.3M; over-allotment added 6M Series A and 6M Series B warrants.","Funds expected to support operations through 2025 and advance ABP-450 biosimilar development.","After offering, shares outstanding ~79.97M; warrants exercisable at $0.625/share post-stockholder approval.","CEO Marc Forth highlighted sufficient capital for 351(k) regulatory pathway and planned BPD Type 2 meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001665","json":"https://secwatch.observer/filing/0001104659-25-001665.json","markdown":"https://secwatch.observer/filing/0001104659-25-001665.md","text":"https://secwatch.observer/filing/0001104659-25-001665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000110465925001665/0001104659-25-001665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000110465925001665/tm2432042d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T09:05:03.716733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}